MHRA paediatric investigation plan
single-stranded 5' capped mRNA encoding the HAs of the influenza virus strains A and B and the N terminal domain (NTD) and receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein. (single-stranded 5' capped mRNA encoding the HAs of the influenza virus strains A and B and the N terminal domain (NTD) and receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein.)
MHRA paediatric investigation plan MHRA-101422-PIP02-24 · Agreement
Key facts
| PIP number | MHRA-101422-PIP02-24 |
|---|---|
| Active substances | single-stranded 5' capped mRNA encoding the HAs of the influenza virus strains A and B and the N terminal domain (NTD) and receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein., (mRNA-1083) |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of influenza and coronavirus disease 2019 (COVID-19) |
| Decision | P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) |
| Published | Nov 29, 2024 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: